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Abstract Introduction: Levels of amyloid b peptide 42 (Ab42), total tau, and phosphorylated tau-181 arewell-
established cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease, but variability in manual
plate-based assays has limited their use. We examined the relationship between CSF biomarkers, as
measured by a novel automated immunoassay platform, and amyloid positron emission tomography.
Methods: CSF samples from 200 individuals underwent separate analysis for Ab42, total tau, and
phosphorylated tau-181 with automated Roche Elecsys assays. Ab40 was measured with a commer-
cial plate-based assay. Positron emission tomography with Pittsburgh Compound B was performed
less than 1 year from CSF collection.
Results: Ratios of CSF biomarkers (total tau/Ab42, phosphorylated tau-181/Ab42, and Ab42/Ab40)
best discriminated Pittsburgh Compound B–positive from Pittsburgh Compound B–negative
individuals.
Discussion: CSF biomarkers and amyloid positron emission tomography reflect different aspects of
Alzheimer’s disease brain pathology, and therefore, less-than-perfect correspondence is expected.
Automated assays are likely to increase the utility of CSF biomarkers.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Alzheimer’s disease (AD) refers to the progressive brain
disease that is characterized by amyloid plaques that are
comprised primarily of amyloid b peptide 42 (Ab42) and
neurofibrillary tangles that are comprised primarily of tau,
including phosphorylated forms of tau. Individuals with
AD are typically asymptomatic (have no apparent cognitive
decline) for one to two decades during the preclinical phase
of the disease [1,2]. As the disease progresses, individuals
enter the symptomatic phase when they develop cognitive
decline that culminates in dementia. Fluid biomarkers can
identify individuals with AD brain pathology who are in
either the preclinical phase or the symptomatic phase of
the disease. Decreases in cerebrospinal fluid (CSF) Ab42
levels and increases in CSF total tau (tTau) and
phosphorylated tau-181 (pTau) may be the earliest markers*Corresponding author. Tel.: (314) 362-3453; Fax (314) 362-2244.
E-mail address: fagana@wustl.edu
https://doi.org/10.1016/j.jalz.2018.01.013
1552-5260/  2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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of AD brain pathology [3–6]. CSF Ab42, tTau, or pTau
individually, and especially the ratios of CSF tTau/Ab42
and pTau/Ab42, predict future cognitive decline of
cognitively normal adults [7,8] and individuals diagnosed
with mild cognitive impairment due to AD [9–12].
It is likely that the use of AD biomarkers will continue to
increase in clinical practice and clinical trials. As demon-
strated by clinicopathological series, the clinical diagnosis
of AD can be incorrect [13], so biomarkers may be helpful
in establishing an accurate diagnosis. CSF biomarkers are
especially useful when the etiology of cognitive impairment
is uncertain and AD is a possible cause [14]. Drug trials now
routinely test CSF or imaging biomarkers in potential partici-
pants after it was found that many individuals enrolled in past
AD drug trials did not have AD brain pathology [15–18]. CSF
biomarkers are also being used in clinical trials to verify that
drugs are having expected biological effects and may
eventually be used as surrogate end points [15,16]. When an
effective drug for AD is available, CSF biomarkers will
become even more important in guiding the diagnosis and
management of patients.
CSF Ab42, tTau, and pTau were the first biomarkers
described for AD [19], and now, molecular imaging bio-
markers have also become well established [20,21].
Radiotracers that bind to b-amyloid (e.g., Pittsburgh
Compound B [PIB], florbetapir, florbetaben, and
flutemetamol) or aggregated tau (e.g., flortaucipir) can
visualize plaques and tangles, respectively, with positron
emission tomography (PET). Although these PET imaging
techniques provide information regarding the degree and
spatial distribution of brain pathology, there are limitations
to their use, including high cost, limited access, use of
radiation, and imaging of only a single type of pathology
per scan [22,23]. A number of studies have previously
evaluated the relationship between CSF biomarkers of AD
and amyloid PET and found a strong inverse correlation
between levels of CSF Ab42 and binding of amyloid PET
tracers [3,5,6,24–33]. The ratio of Ab42 with another AD
biomarker (e.g., tTau/Ab42, pTau/Ab42, or Ab42/Ab40)
may provide the best correlation with amyloid PET
measures [24,30,32].
The use of CSF biomarkers has been limited by a number
of technical factors. There has been substantial variability in
the intralaboratory and interlaboratory performance of the
three most commonly used commercial enzyme-linked
immunosorbent assays (ELISAs) for CSF Ab42, tTau, and
pTau: INNOTEST, AlzBio3, and Meso Scale Discovery. Is-
sues with these assays include high lot-to-lot variability [34]
and between-laboratory variability associated with differ-
ences in laboratory procedures and analytical techniques
because the assays are run manually [12,35–37].
Practically, because most assays are based on the 96-well
plate immunoassay format, laboratories must await a large
number of samples to financially justify analysis, which in
turn leads to delays in obtaining results. The lack of stan-
dardized reference materials for quantitation of these analy-
tes has made it difficult to compare absolute values across
assays and studies [38]. Taken together, these issues have
prevented the establishment of universal diagnostic cutoffs
for CSF biomarkers and decreased the potential utility of
CSF biomarkers in the clinic and in clinical trials.
Next-generation automated assay platforms are being
developed to overcome the shortcomings of previous assay
systems. Roche Diagnostics has developed Elecsys assays
that utilize the automated cobas 601 analyzer. This assay
platform exhibits high degrees of precision, accuracy, reli-
ability, and reproducibility, with very low variability, in large
part due to its automation [39]. We tested this novel assay
platform using CSF samples obtained from individuals
who had also undergone amyloid PET. CSF Ab42, tTau,
and pTau were measured separately with Elecsys assays.
CSFAb40 was measured with a standard plate-based ELISA
[24]. We then examined the relationship between cortical
amyloid load as defined by PIB PET and CSF Ab42,
Ab40, tTau, pTau, and three ratios of Ab42 with another
AD biomarker (tTau/Ab42, pTau/Ab42, and Ab42/Ab40).
2. Materials and methods
2.1. Participants, standard protocol approvals, and
consents
Participants were community-dwelling volunteers
enrolled in studies of normal aging and dementia at the
Knight Alzheimer’s Disease Research Center at Washington
University in St. Louis. Participants had no neurological,
psychiatric, or systemic medical illness that might compro-
mise longitudinal study participation and no medical contra-
indication to lumbar puncture (LP) or PET. All participants
underwent clinical assessments that included the Clinical
Dementia Rating (CDR) [40]. APOE genotype was obtained
from the Knight Alzheimer’s Disease Research Center Ge-
netics Core [41]. All procedures were approved by theWash-
ington University Human Research Protection Office, and
written informed consent was obtained from each partici-
pant.
Participants included in this study underwent a clinical
assessment, LP, and PIB PET within a 365-day period. Of
participants who met these criteria, 200 were selected based
on cortical amyloid load by PIB PET (25% PIB-positive and
75% PIB-negative based on a previously established cutoff
[42]). We chose to include more PIB-negative participant
samples to enrich for discordant (PIB-negative and CSF
biomarker positive) cases. Furthermore, we chose partici-
pants with a broad range of CSF Ab42 values based on pre-
vious data from plate-based assays. Selection was
independent of participant demographics and clinical status.
2.2. CSF collection, processing, and analysis
CSF was collected under standardized operating proced-
ures. Participants underwent LP at 8 AM after overnight fast-
ing. Twenty to 30 mLs of CSF was collected in a 50-mL
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polypropylene tube via gravity drip using an atraumatic
Sprotte 22 gauge spinal needle. The entire samplewas gently
inverted to disrupt potential gradient effects and centrifuged
at low speed to pellet any cellular debris. Five hundred mi-
croliters of CSF was aliquoted into polypropylene tubes
and stored at 280C as previously described [5].
Ab42, tTau, and pTau were measured with the corre-
sponding Elecsys immunoassays utilizing the Roche cobas
e 601 analyzer—a fully automated system. The Elecsys im-
munoassays are electrochemiluminescence immunoassays
using a quantitative sandwich principle with a total assay
duration of 18 minutes. Pristine aliquots from the selected
cohort were measured according to the Roche study protocol
(RD002967) written specifically to measure these samples.
Ab40 concentrations were measured with a plate-based
ELISA from IBL International (Hamburg, Germany) ac-
cording to the manufacturer’s protocol. A single lot of assays
for each analyte (either Elecsys for Ab42, tTau, and pTau or
IBL for Ab40) was used to measure all samples to avoid lot-
to-lot variability.
2.3. Amyloid PET imaging
Participants underwent a 60-minute dynamic scan with
11[C] PIB [43]. PET imaging was performed with a Siemens
962 HR 1 ECAT PET or Biograph 40 scanner (Siemens/
CTI, Knoxville, KY). Structural magnetic resonance imaging
using MPRAGE T1-weighted images was also acquired.
Structural magnetic resonance images were processed using
FreeSurfer [44] (http://freesurfer.net/) to derive cortical and
subcortical regions of interest used in the PET processing
[45,46]. Regional PIB values were converted to standardized
uptake value ratios (SUVRs) using cerebellar gray as a
reference and partial volume corrected using a regional
spread function approach [45,46]. Values from the left and
right lateral orbitofrontal, medial orbitofrontal, precuneus,
rostral middle frontal, superior frontal, superior temporal,
and middle temporal cortices were averaged together to
represent a mean cortical SUVR. PIB positivity was defined
as amean cortical SUVR. 1.42 [42], which is commensurate
with a mean cortical binding potential of 0.18 that has previ-
ously been used to define PIB positivity [45].
2.4. Statistical analyses
Characteristics of PIB-positive and PIB-negative groups
were compared using t-tests for continuous variables and
c2 tests for categorical variables. Performance of the Elecsys
assay has not yet been formally established for measuring
Ab42 concentrations , 200 pg/mL or . 1700 pg/mL.
None of the samples used for this study had Ab42 concentra-
tions, 200 pg/mL. Concentrations of Ab42. 1700 pg/mL
were extrapolated based on the calibration curve. These
values are restricted to research use and are not for clinical
decision making. Values for CSF biomarkers, including sin-
gle analytes and ratios, were compared to PIB PET SUVR
using Spearman correlation.
Receiver operating characteristic (ROC) analyses were
performed to determine the cutoffs for each CSF biomarker
analyte and ratio that best distinguished PIB-positive from
PIB-negative individuals. Positive percent agreement (PPA)
was defined as the percent of PIB-positive individuals who
were positive by a CSF biomarker measure. Negative percent
agreement (NPA) was defined as the percent of PIB-negative
individuals whowere negative by a CSF biomarker measure.
Overall percent agreement was defined as the sumof the PIB-
positive individuals who were positive by a CSF biomarker
measure and the PIB-negative individuals whowere negative
by a CSF biomarker measure divided by the entire cohort
size. The CSF biomarker single analyte or ratio value with
the highest Youden index (PPA 1 NPA 2 1) was selected
as the cutoff value. Analyses were performed with GraphPad
Prism version 6.07 (GraphPad Software, La Jolla, CA).
3. Results
3.1. Participant characteristics
CSF samples from 198 individuals were analyzed (see
Table 1 for participant characteristics). Samples from two
participants in the selected cohort were omitted because of
failure of PIB PET quality control (i.e., movement artifact
or out of LP-PETwindow of 365 days). The average absolute
interval from LP to PIB PET was 67 6 78 days
(mean 6 standard deviation). Most of the participants
(n 5 176, 89%) were cognitively normal at the time of
CSF collection with a CDR of 0, but some (n 5 22, 11%)
Table 1
Participant characteristics
Characteristic PIB negative PIB positive P
n 148 50
CDR 0/0.5/1/2/3 141/7/0/0/0 35/11/3/1/0
CDR . 0 (%)* 5% 30% ,.0001
MMSEy 29.1 6 1.2 28.0 6 3.0 ,.001
Age at LP (years)y 64.2 6 9.6 72.5 6 7.2 ,.0001
Gender (% male)* 34% 58% ,.01
Education (years)y 15.9 6 2.5 15.5 6 3.0 N.S.
APOE ε4 positive (%)* 31% 56% ,.01
PIB mean cortical SUVRy 1.04 6 0.12 2.40 6 0.70 ,.0001
Elecsys Ab42, pg/mLy 1428 6 610 789 6 256 ,.0001
IBL Ab40, pg/mLy 13,950 6 4347 15,310 6 4147 .06
Elecsys tTau, pg/mLy 191 6 76 309 6 127 ,.0001
Elecsys pTau, pg/mLy 16.7 6 7.8 30.3 6 14.8 ,.0001
Elecsys tTau/Ab42y 0.150 6 0.090 0.420 6 0.173 ,.0001
Elecsys pTau/Ab42y 0.013 6 0.010 0.041 6 0.020 ,.0001
Elecsys Ab42/IBL Ab40y 0.103 6 0.028 0.052 6 0.014 ,.0001
Abbreviations: CDR, clinical dementia rating; MMSE, Mini–Mental
State Examination; PIB, Pittsburgh Compound B; tTau, total tau; pTau,
phosphorylated tau-181; Ab42, amyloid b peptide 42; SUVR, standardized
uptake value ratio; LP, lumbar puncture; IBL, IBL International (Hamburg,
Germany).
*Percent, P values by c2 test.
yMean 6 standard deviation, P values by student’s t-test.
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had very mild (CDR 0.5) or mild (CDR 1) dementia. By
design, 50 (w25%) of the individuals were PIB-positive
(mean cortical SUVR . 1.42). As expected, individuals
who were PIB-positive were more likely to be cognitively
impaired (30% vs. 5%, P , .0001), older (72.5 6 7.2 vs.
64.2 6 9.6 years, P , .0001), and carry an APOE ε4 allele
(56% vs. 31%, P , .01). In addition, PIB-positive individ-
uals were more likely to be male (P , .01) in this cohort.
3.2. Correlations between CSF biomarker measures and
PIB binding
The Roche cobas e 601 analyzer was used to measure
levels of Ab42, tTau, and pTau with the corresponding
Elecsys assays. At the time of analysis, this platform did
not have an Ab40 assay available. Therefore, Ab40 levels
were measured with the IBL Ab40 ELISA kit. The values
for Ab42, Ab40, tTau, or pTau versus PIB mean cortical
SUVRwere plotted (Fig. 1, upper panels). By Spearman cor-
relation analysis, PIB binding was negatively correlated with
CSFAb42 (r520.45, P, .0001) and positively correlated
with CSF Ab40 (r 5 0.20, P , .01), tTau (r 5 0.46,
P , .0001), and pTau (r 5 0.51, P , .0001). PIB binding
was positively correlated with tTau/Ab42 (r 5 0.66) and
pTau/Ab42 (r 5 0.66) and negatively correlated with
Ab42/Ab40 (r 5 20.63), all at P , .0001 (Fig. 2, upper
panels). Notably, tTau and pTau were almost perfectly corre-
lated (r 5 0.98, P , .0001).
3.3. Determination of cutoffs for CSF biomarker measures
ROC analyses were performed to determine the cutoffs
for each biomarker analyte and ratio that best distinguished
PIB status (positive or negative). Because PIB PET is not the
gold standard for brain amyloid deposition (autopsy is the
gold standard), we refer to PPA rather than sensitivity and
NPA rather than specificity. The cutoffs selected are depicted
in the lower panels of Fig. 1 for Ab42 (A), Ab40 (B), tTau
(C), and pTau (D) and Fig. 2 for tTau/Ab42 (A), pTau/
Ab42 (B), and Ab42/Ab40 (C). The lower panels also indi-
cate the associated PPA, NPA, and overall percent agreement
for each CSF measure with PIB status. The ROC curves and
a summary of cutoff characteristics for all biomarker mea-
sures are shown in Fig. 3. Inspection of the ROC curves
shows that Ab42/Ab40 and Ab42 have a lower NPA for a
given PPA at most potential cutoff values compared to the
other ratios or single analytes, respectively (e.g., at a cut
point with a PPA of 0.50 for all analytes, the NPA for
Ab42/Ab40 is lower than for tTau/Ab42 and pTau/Ab42
and the NPA for Ab42 is lower than for tTau and pTau).
For the cutoff values selected, the PPAs for tTau/Ab42,
pTau/Ab42, and Ab42/Ab40 were high (0.92–0.96) with
somewhat lower NPAs (0.82–0.89). The PPA and NPA for
Ab42, tTau, and pTau as single analytes (0.68–0.90 for
PPA and 0.73–0.83 for NPA) were not as high as the three
ratios but were superior to Ab40 (0.60 for PPA and 0.58
for NPA).
Levels of Ab42 . 1700 pg/mL were extrapolated and
therefore estimated, so we performed alternative analyses
to determine whether inaccuracies in high Ab42 values
could bias our results. We reanalyzed our data treating indi-
viduals with Ab42 . 1700 pg/mL as biomarker negative,
regardless of the level of other analytes (Supplementary
Fig. 1). Notably, all 40 individuals in our cohort with
Ab42 values . 1700 pg/mL were PIB-negative. We found
Fig. 1. Single CSF analyte values compared to PIB binding. PIB binding was negatively correlated with CSFAb42 (A) and positively correlated with CSFAb40
(B), tTau (C), and pTau (D). Each point represents the analyte value and PIB mean cortical SUVR for one individual. The horizontal red dashed lines represent
the cutoff values that best distinguish between PIB-positive and PIB-negative individuals. The horizontal gray dotted line represents the upper limit of quan-
titation for Ab42 (A). For the upper panels, the vertical red dashed lines represent the established cutoff value for PIB positivity (SUVR. 1.42). The Spearman
correlation coefficient (r) with 95% confidence intervals is indicated. For the lower panels, individuals were dichotomized into PIB-negative (SUVR 1.42) and
PIB-positive (SUVR. 1.42) groups. The lower panels indicate the cutoff values and associated positive percent agreement (PPA), negative percent agreement
(NPA), and overall percent agreement (OPA) for each CSF analyte with PIB binding. Abbreviations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B;
tTau, total tau; pTau, phosphorylated tau-181; Ab42, amyloid b peptide 42; SUVR, standardized uptake value ratio.
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minimal changes in the results, likely because individuals
with Ab42 . 1700 pg/mL typically do not have significant
AD brain pathology and therefore rarely have elevated
tTau or pTau. The only small differences we found were
that the NPA for tTau/Ab42 increased from 0.85 to 0.86
and the NPA for Ab42/Ab40 increased from 0.82 to 0.83
when individuals with Ab42. 1700 pg/mLwere considered
biomarker negative. We therefore concluded that estimation
of Ab42 values . 1700 pg/mL did not affect concordance
with PIB PET.
3.4. Concordance of CSF ratios and PIB binding
Because the three CSF ratios (tTau/Ab42, pTau/Ab42,
and Ab42/Ab40) performed well in discriminating PIB-
positive and PIB-negative individuals, we next examined
the degree to which the CSF ratios were concordant with
other CSF ratios and with PIB status (Table 2). Biomarker
status (positive or negative according to the cutoffs previ-
ously discussed) was visualized in scatterplots of CSF tTau
versus Ab42 (Fig. 4A), pTau versus Ab42 (B), and Ab40
versus Ab42 (C). There was a concordance of all three
CSF ratios and PIB PET in 166 of 198 individuals in our
cohort (84%): all three CSF ratios were positive in 46 of
the 50 PIB-positive individuals (92%) and all three CSF ra-
tios were negative in 120 of the 148 PIB-negative individuals
(81%). Four individuals were PIB-positive but either all
three CSF ratios were negative (two individuals) or Ab42/
Fig. 2. CSF ratios compared to PIB binding. PIB binding is positively correlated with CSF tTau/Ab42 (A), pTau/Ab42 (B), and Ab42/Ab40 (C). Each point
represents the ratio of analytes and PIB mean cortical SUVR for one individual. The horizontal red dashed lines represent the cutoff values that best distinguish
between PIB-positive and PIB-negative individuals. For the upper panels, the vertical red dashed lines represent the established cutoff value for PIB positivity
(SUVR. 1.42). The Spearman correlation coefficient (r) with 95% confidence intervals is indicated. For the lower panels, individuals were dichotomized into
PIB-negative (SUVR  1.42) and PIB-positive (SUVR. 1.42) groups. The lower panels indicate the cutoff values and associated positive percent agreement
(PPA), negative percent agreement (NPA), and overall percent agreement (OPA) for each CSF analyte with PIB binding. Abbreviations: CSF, cerebrospinal
fluid; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Ab42, amyloid b peptide 42; SUVR, standardized uptake value ratio.
Fig. 3. Receiver operator characteristic (ROC) curves for CSF biomarkers
compared to PIB binding. For ROC analysis, individuals were dichotomized
into PIB-negative (SUVR 1.42) and PIB-positive (SUVR. 1.42) groups.
For each CSF biomarker measure, the table indicates the cutoff values and
associated positive percent agreement (PPA), negative percent agreement
(NPA), and area under the ROC curve (AUC) for the measure compared
to PIB status. 95% confidence intervals are included in parentheses. Abbre-
viations: CSF, cerebrospinal fluid; PIB, Pittsburgh Compound B; SUVR,
standardized uptake value ratio.
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Ab40 was positive but tTau/Ab42 and pTau/Ab42 were
negative (two individuals). Sixteen individuals were PIB-
negative, but all three CSF ratios were positive. Twelve indi-
viduals were PIB-negative and had partial discordance of the
CSF ratios; most (10 of 12) had high Ab42/Ab40.
There was a concordance of PIB PET and all three CSF
ratios in 21 of the 22 individuals in our cohort with cognitive
impairment (CDR. 0): Fifteen individuals were positive by
all measures and six were negative by all measures. One in-
dividual rated CDR 0.5 was PIB-negative, Ab42/Ab40 and
tTau/Ab42 positive, but pTau/Ab42 negative. The six indi-
viduals rated CDR . 0 who were negative by both PET
PIB and all three CSF ratios likely have a non-AD cause
of their cognitive symptoms. In all 198 cases, tTau/Ab42
was positive if pTau/Ab42 was positive, but tTau/Ab42
was positive in some individuals (n 5 5) when pTau/Ab42
was negative. Notably, many of the individuals with partial
discordance of the CSF ratios had values close to the cutoffs
and therefore may be in a transitional or borderline stage (see
Table 2).
4. Discussion
Overall, we found a high concordance between PIB PET
and CSF biomarkers of AD as measured by the Elecsys as-
says. Ratios of CSF biomarkers that included Ab42 (tTau/
Ab42, pTau/Ab42, and Ab42/Ab40) best distinguished
PIB-positive from PIB-negative individuals. All three CSF
ratios were positive in 46 of the 50 PIB-positive individuals
(92%), and all three CSF ratios were negative in 120 of the
148 PIB-negative individuals (81%). Out of the 32 individ-
uals (16% of the cohort) with discordance between the three
CSF ratios and PIB PET, 28 individuals were negative by
PIB but positive by at least one CSF ratio.
Previous reports have identified amyloid PET–negative in-
dividuals with positive CSF biomarkers [3,5,6,42]. Recent
work has demonstrated that amyloid PET–negative but CSF
biomarker–positive individuals have increased rates of amy-
loid accumulation, suggesting these individuals have early
AD brain pathology and are likely to develop amyloid PET
positivity [3,42]. While CSF biomarkers and amyloid PET
are both markers of amyloid pathology, CSF biomarkers
indicate the state of Ab42 production and clearance at the
time of LP while amyloid PET images the accumulation of
neuritic amyloid plaques over many years. In addition,
amyloid PET tracers are designed to bind to neuritic
amyloid plaques [47], whereas CSF biomarkers could be
more sensitive to deposition of both neuritic amyloid plaques
and diffuse amyloid plaques [48]. It appears likely that CSF
biomarkers becomepositivevery early in the courseof thedis-
ease, before sufficient amyloid has accumulated to create an
amyloid PET signal. Therefore, less-than-perfect correspon-
dence of PIB PET and CSF biomarkers is expected and may
reflect differences in AD brain pathology.
Notably, we found that in cases of partial discordance be-
tween CSF biomarker ratios and PIB PET (when some, but
not all, CSF biomarker ratios agreed with PIB PET),
Ab42/Ab40 was typically the positive ratio (nine of 11
cases) in PIB-negative cases and was the sole positive ratio
in two PIB-positive cases. These findings suggest that
abnormal Ab42/Ab40 may be the earliest indicator of amy-
loid brain pathology, potentially reflecting stage 1 of preclin-
ical AD (amyloid deposition but no abnormalities in tTau or
pTau) [49]. Compared to Ab42, the ratio of Ab42/Ab40 may
better reflect deposition of amyloid because it may
normalize for individual variation in overall amyloid pro-
duction [24]. However, many of the cases with partial discor-
dance of CSF ratios have borderline values and selecting
different cutoffs would change the concordance of the ratios
somewhat. Larger studies are required to determine whether
Ab42/Ab40 becomes altered at an earlier stage than tTau/
Ab42 and pTau/Ab42. Interestingly, we also found that
tTau and pTau were almost perfectly correlated (r 5 0.98,
P , .0001) in our cohort. It is possible that tTau and pTau
may be less highly correlated in a cohort enriched for
non-AD dementia—this is a topic for future studies.
Table 2
Concordance between CSF tTau/Ab42, pTau/Ab42, Ab42/Ab40, and PIB PET
Characteristic
n (% of PIB
group)
CDR PIB SUVR tTau/Ab42 pTau/Ab42 Ab42/Ab40
0/0.5/1/2/3 .1.42 .0.211 .0.0198 ,0.075
PIB positive, n 5 50
PIB 1 and all CSF ratios 1 46 (92) 31/11/3/1/0 2.45 6 0.71 0.440 6 0.165 0.0434 6 0.0194 0.050 6 0.011
PIB 1, all CSF ratios 2 2 (4) 2/0/0/0/0 1.74 6 0.23 0.175 6 0.005 0.0156 6 0.0006 0.089 6 0.007
tTau/Ab42 and pTau/Ab42 2, Ab42/Ab40 1 2 (4) 2/0/0/0/0 1.98 6 0.07 0.193 6 0.012 0.0172 6 0.0006 0.069 6 0.003
PIB negative, n 5 148
All CSF ratios 2 120 (81) 114/6/0/0/0 1.03 6 0.10 0.120 6 0.030 0.0104 6 0.0026 0.114 6 0.019
All CSF ratios 1 16 (11) 16/0/0/0/0 1.16 6 0.14 0.334 6 0.162 0.0322 6 0.0228 0.050 6 0.011
Ab42/Ab40 1, tTau/Ab42, and pTau/Ab42 2 6 (4) 6/0/0/0/0 0.98 6 0.08 0.189 6 0.013 0.0165 6 0.0019 0.067 6 0.005
Ab42/Ab40 and tTau/Ab42 1, pTau/Ab42 2 4 (3) 3/1/0/0/0 1.06 6 0.16 0.222 6 0.003 0.0192 6 0.0003 0.066 6 0.007
tTau/Ab42 and pTau/Ab42 1, Ab42/Ab40 2 1 (1) 1/0/0/0/0 1.05 0.222 0.0203 0.083
tTau/Ab42 1, Ab42/Ab40, and pTau/Ab42 2 1 (1) 1/0/0/0/0 1.32 0.223 0.0183 0.084
Abbreviations: CSF, cerebrospinal fluid; CDR, clinical dementia rating; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Ab42,
amyloid b peptide 42; SUVR, standardized uptake value ratio; PET, positron emission tomography.
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The Roche Elecsys assays and other automated assays for
CSF biomarkers are likely to increase the utility of CSF bio-
markers in research, clinical trials, and clinical diagnosis.
Further studies are needed to examine the concordance be-
tween CSF biomarkers of AD as measured by the Elecsys as-
says and other amyloid PET tracers. Studies are also needed
to evaluate whether CSF biomarkers of AD as measured by
the Elecsys assays predict future cognitive decline. It is un-
clear whether the same cutoff values that correspond with
amyloid PET status will also best predict cognitive decline.
Finally, comparison of CSF biomarkers with brain autopsy
data in cases with a short CSF collection to autopsy interval
would be helpful in demonstrating that CSF biomarkers as
measured by the Elecsys assays are strongly correlated
with AD brain pathology.
Given the high degree of precision, accuracy, reliability,
and reproducibility of the Elecsys assays [39], it is possible
that an Elecsys CSF biomarker measure could be found that
is reproducible across all sites worldwide and is highly pre-
dictive of AD brain pathology. It is important to note that
preanalytical factors may affect CSF biomarker values,
especially of Ab42. Therefore, further refinement of CSF
testing for AD will require rigorous standardization of prea-
nalytical factors, including sample collection and process-
ing. It will also be important to further define when it is
appropriate for clinicians to perform CSF testing for AD.
When a disease-modifying agent for AD becomes available,
many patients will be interested in learning their amyloid
status, and it will be important to have clear guidelines in
place for all aspects of CSF testing.
Fig. 4. Concordance of CSF ratios and PIB binding. The status (positive or negative according to CSF ratios or PIB binding) was evaluated in scatterplots of CSF
tTau versus Ab42 (A), pTau versus Ab42 (B), and Ab40 versus Ab42 (C). Each point represents CSF biomarkers in one individual. Solid points have a positive
biomarker status (as defined in the plot titles) and open points have a negative status. The horizontal red dashed lines represent the cutoff values for CSF tTau (A),
pTau (B), and Ab40 (C). The vertical red dashed lines represent the cutoff value for Ab42. The vertical gray dotted lines represent the upper limit of quantitation
for Ab42. The sloped solid red lines represent the cutoff values for tTau/Ab42 (A), pTau/Ab42 (B), and Ab40/Ab42 (C). Abbreviations: CSF, cerebrospinal
fluid; PIB, Pittsburgh Compound B; tTau, total tau; pTau, phosphorylated tau-181; Ab42, amyloid b peptide 42.
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RESEARCH IN CONTEXT
1. Systematic review: Cerebrospinal fluid (CSF) bio-
markers of Alzheimer’s disease are used in research,
in clinical trials, and to inform clinical diagnosis.
Technical factors, including lot-to-lot variability in
assays, have limited the utility of CSF assays.
2. Interpretation: CSF biomarker values measured with
Roche Elecsys assays were compared to Pittsburgh
Compound B (PIB) positron emission tomography.
We found that ratios of CSF biomarkers that included
amyloid b peptide 42 (Ab42) (total tau/Ab42, pTau/
Ab42, and Ab42/Ab40) best distinguished between
individuals whowere PIB-positive and PIB-negative.
Discordance between CSF biomarkers and PIB posi-
tron emission tomography may occur because CSF
biomarkers measure different aspects of Alzheimer’s
disease brain pathology.
3. Future directions: Automated assays for CSF bio-
markers are likely to improve the reliability of CSF
testing for Alzheimer’s disease. Further work is
needed to standardize preanalytical factors.
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